Diagnosis and Staging Flashcards

1
Q

Medical History

A
Essential part of a ca. diagnosis
-differential diagnosis
-drives workup
-family hx
-known risk factor
not all cancers present with symptoms
suspicious signs and symptoms that warrant further work-up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Red Flag symptoms?

A
unexplained fatigue
wt loss >10lbs
night sweats
bleeding/bruising
unexplained fever
poor healing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

general guide for suspicious symptoms

A

cancer is not usually the cause of these symptoms
abnormal signs and symptoms lasting several weeks: seek care
early stage cancer usually not painful
do not wait to feel pain before seeking care
symptoms not caused by cancer cells themselves

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

symptoms usually caused by:

A

increasing tumor burden
organ dysfunction related to tumor
cutaneous changes related to tumor
(cancer affecting other organs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Suspicious symptoms ROS General

A
fatigue and/or weakness without cause
night sweats (NOT sweating at night, soaked)
prolonged fever > 1 week, without etiology, low grade
generalized pruritis (bee symtoms)
weight changes: gain or loss without cause or purpose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Suspicious symptoms ROS HEENT

A

hoarseness that does not resolve (thyroid, throat, lung, lymph)
difficulty swallowing
prolonged non-tender, enlarged lymph nodes (axilla or groin)
expistaxis - prolonged (leukemia/bone marrow)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Suspicious symptoms ROS respiratory

A

non-resolving cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Suspicious symptoms ROS chest/breast

A

change in size or shape of breast or nipple
change in texture or skin
edema of all or part of a breast (even if no distinct lump)
breast skin irritation or dimpling
breast or nipple pain
nipple retraction
erythema, scaling, or thickening of nipple or skin
nipple discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Suspicious symptoms ROS GI

A

early satiety
pain or discomfort after eating (normal with gallblader probl)
changes in appetite (usually anorexia)
hematochezia (blood in stool - bright)
abdominal pain
change in bowel movements: diarrhea or constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Suspicious symptoms ROS Genitourinary

A

dysuria
hematuria
abnormal vaginal bleeding or discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Suspicious symptoms ROS integumentary

A

new or changing mole (thin ABCDs of skin ca.)
non-healing lesion
thickening or new lump on or under skin (lymph node)
petechiae/purpura

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Suspicious symptoms ROS Neurologic

A

headaches - especially with N/V or vision changes
new onset weakness
acute onset seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pt education: symptoms

A

7 warning signs spell CAUTION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CAUTION

A

C - change in bowel or bladder habits
A - a sore that doe snot heal in a normal amount of time
U - unusual bleeding or discharge
T - thickening of breast tissue or a lump
I - indigestion and/or difficulty swallowing
O - obvious changes to moles or warts
N - nagging cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Physical Exam

A

head to to

Performance status - use to assist in determining patients’ ability to tolerate treatment options

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Performance status

A

-use to assist in determining patients’ ability to tolerate treatment options
-used in clinical trials to determine eligibility
–most use ECOG status
–phase I vs phase III or IV, earlier trial inc PS needed
several different scales:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

2 Performance scales

A

ECOG * eastern cooperative oncology group: 0-5 dead

Karnofsky - 0%-100%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lab studies

A

Evaluate baseline information prior to developing treatment plan
Universal stand of care labs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

baseline information

A

marrow function
hepatic function
renal function
tumor lysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Universal standard of care labs

A

CBC with differential
basic metabolic panel
hepatic function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Common labs

A

coagulation panel
pancreatic enzymes
lactate dehydrogenase (LDH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Imaging studies

A

confirms tumor existence and location
confirms extent of spread of tumor if metastasized
anatomical Vs functional status (CT vs PET)

*information for biopsy/surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Anatomical studies

A

image the anatomy to help detect abnormalities

  • xrays
  • computed tomogaphy (CT)
  • mammography (type of xray)
  • magnetic resonance imaging (MRI)
  • nuclear sans (bone scan..)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Functional studies

A

image the working processes of the body

  • Tissue metabolism, organ efficiency, neural signaling
  • magnetic resonance spectroscopy
  • Positron emission tomography (PET) - hot spots
  • octreotide scan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

X-ray

A
2 day image
quick and efficient
inexpensive
non-invasive
used often in multiple myeloma: quickly see lytic bone lesions
limitations: obesity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Ultasound in cancer diagnosis

A

non-invasive
high frequency sound waves
images made from reflection of waves
uses: liver, kidney, breast, ovarian, effusions (ascities, peicardial), transvaginal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Computed tomography (CT)

A

most common diagnostic imaging tool in onc
combines xrays with sophisticated computers
3D omputer model
allows examine of body one slice at a time to pinpoint specific areas
caution in use of IV contrast with renal disease pts (check CREAT levels, metformin, shelfish allergy)
contrast - helps to highlight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Magnetic Resonance imaging MRI

A

uses a magnetic field and radio waves
create detailed images of the organs and tissues
magnetic field temporarily realigns hydrogen atoms in your body
not exposed to ionizing radiation
preferred for bone, musculoskeletal, CNS
limitations: metal implants, tolerability (claustrophibia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Positron Emission Tomography (PET)

A

reveal tissue and organ function
uses radioactive drug (tracer), usually glucose
tracer collects in areas that have higher level of chemical activity - often correspond to areas of disease, can correspond with normal tissue, bright spots or “hot spots”
used mainly for lymphoma and melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Bone scan

A

inject radioactive tracer: F-FDG, sugar
metabolically active areas uptake the tracer and light up on images
reported uptake as an SUV
not all tumors will uptake tracer b/c slow growing (broncho-alveolar)
expensive
diagnostic for: esophageal, colorectal, melanoma, lymphoma, NSCLC, thyroid, breast, lung nodunes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

GI series

A
barium studies
upper GI series
lower GI series
limitations: fasting required, bowel prep
useful for assessment in colon cancer
*must tolerate drinking barium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Diagnosis

A

accurate diagnosis needed to determine treatment
must have tissue to make diagnosis (biopsy)
tissue or cells are examined histologically to determine malignancy from benign
microscopic diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Biopsy based on:

A

symptoms reported by patient
physical examination findings
incidental findings on xray or any other test done for different reason
screening tests

34
Q

Tissue diagnosis

A

biopsy
diagnosis requires tissue
histology = microscopic structure of tissue
cytology = structure and fn of cells

35
Q

sites most likely to obtain adequate tissue

A
Fine needle aspiration (FNA)
Core needle biopsy
stereostatic biopsy
excisional
incisional
CT guided bx
36
Q

Diagnostic procedures

A
endoscopy
colonoscopy
laparoscopy
bronchoscopy
throcaoscopy
metiastionoscopy
37
Q

Pathology

A

histologic exam: tissue sliced thinly, viewed under scope

Cytology exam: cells from fluid

38
Q

cytology exam tissue sources

A

urine, CSF, sputum, peritoneal fluid, pleural fluid, cervical/vaginal smears, blood

39
Q

Benign tumor

A

slow growth rate
grows within a capsule of fibrous tissue
no invasion of adjacent tissue = no mets
cytology is uniform with well differentiated cells that look like origin cell

40
Q

Malignant tumor

A

high mitotic rate = rapid growth
not encapsulated = invades surrounding tissue
cytology poorly differentiated

41
Q

primary tumor

A

site of origin

42
Q

secondary tumor

A

used to describe a metastatic tumor or a new primary

43
Q

6 cancer categories

A
Carcinoma
Sarcoma
Myeloma
Mixed type
Leukemia
Lymphoma
44
Q

Carcinoma

A

epithelial origin or cancer of the internal or external lining of the body
account for 80-90% of all cancer cases
2 major subtypes:
–1. adenocarcinoma = develops in an organ or gland
–2. squamous cell carcinoma = originates in the squamous epithelium

45
Q

Sarcoma

A

originates in supportive and connective tissues
generally occurs in young adults
most common sarcoma often develops as a painful bone mass
resemble the tissue in which they grow

46
Q

Myeloma

A

originates in the plasma cells of bone marrow

47
Q

Mixed types

A

components may be within one category or from different categories
ex. adenosquamous carcinoma
-need bone marrow transplants,
hard to treat: many cells

48
Q

Leukemia

A

“liquid tumors”, blood cancers
cancers of the bone marrow *site of WBC production
overproduction of immature WBC = blasts
blasts immature, do not function properly –> immune suppression
RBC affects due to fatigue r/t anemia

dec platelets & RBC –> symptoms: bleeding, fatigue, anemia

49
Q

Lymphoma

A

develops in glands or nodes of lymph system
Lymph system: network of vessels, nodes, & organs (spleen, tonsils, thymus), filters body fluids, produces infection fighting WBC (lymphocytes)
extra-nodal lymphomas occur in specific organs (stomach, breast, brain)

50
Q

Lymphoma 2 categories

A

Hodgkin Lymphoma- reed-sternberg cells in hodgkins’ diagnostically distinguishes
Non-hodgkin lymphoma

51
Q

Immunohistochemical Stains (IHC)

A

principle of antibodies binding specifically to antigens in biological tissues
detect the antigens (proteins) in cells of tissue section
used to diagnose some cancers, identifies site of origin
cellular activity within cancer highlighted by staining
distinguish benign or malignant

52
Q

IHC common markers

A

fluorescent dyes
enzymes
radioactive elements

antigens: ER/PR/Her2/Neu/PSA/Ki67

53
Q

Flow Cytometry

A

laser based, biophysical testing
cell sorting and counting, biomarker detection and protein engineering
suspends cells in a stream of fluid and passing them by an electronic detection
routinely used in diagnosis of hematologic malignancies, indicative for treatment
uses in research, clinical practices and trials
used in: lymphomas, leukemias, bladder cancer
specimins from biopsy, effusions, bone marrow, bladder cytology

54
Q

Cytogenetics

A

-concerned with structure and function of the cell, esp chromosomes
-FISH: flourescence in situ hybridization
PCR: polymerase chain reaction

55
Q

FISH

A

flourescence in situ hybridization

test that “maps” the genetic material in a person’s cells

56
Q

PCR

A

polymerase chain reaction
amplifies the genetic material to a level that can be detected
looks at copies of a DNA sequence for relevance to diagnosis (abnormal)

57
Q

Ideal tumor marker

A

ideal only from 1 tissue/cancer type… but not the case
not always correct/accurate/predictive
Specific - 1 tumor only
Sensitive - present or detectible early
Proportional - level reflect tumor mass
Predictive - able to foretell disease response and recurrence
Feasible - cost effective and commercially available

58
Q

PSA tumor marker (ideal?)

A

occurs regularly with aging

but if worsening condition, likely progressing with disease

59
Q

Tumor markers

A

substance that can be found in body when cancer is present
-in blood, urine, or other body fluids/ tissues
-sometimes by normal cells too
-different cancers types have different markers
not ideal bc normal cells can produce markers
not useful for screening

60
Q

When do we use tumor markers?

A

used to watch for treatment response
never treat a number*
not useful for screening

61
Q

Common tumor markers

A
ALK
Alpha-fetoprotein
Beta 2 microtubulin
beta-human chorionic gonadotroping
BCR-Able fusion gene
BRAF
CA15
CA19
CA125
Calcitonin
Carcinoembryonic antigen
CD20
Chromogranin A
Chromosomes 3,7, 17 and 9p21
Cytokeratin
62
Q

BCR-ABL fusion gene

A

Chronic myeloid leukemia
from blood and bone marrow
to confirm diagnosis and monitor disease

63
Q

BRAF mutation V60E

A

cutaneous melanoma and colorectal cancer
tumor tissue
to predice response to targeted therapy

64
Q

CA125

A

ovarian cancer
blood
to help in diagnosis, assessment of response to treatment, or evaluation of recurrence

65
Q

Estrogen Receptor/Progesterone Receptor ER/PR

A

breast cancer
tumor tissue
to determine whether treatment with hormone therapy is apporpriate

66
Q

HER2/neu

A

breast, gastric and esophageal cancer
tumor
to determine wheter treatment with Trastuzumab is appropriate

67
Q

21 Gene signature (Oncotype DX)

A

breast cancer
tumor
to evaluate risk of recurrence

68
Q

70-Gene signature (mammaprint)

A

breast
tumor
to evaluate risk of recurrence

69
Q

Grading

A

pathologist grades tumor
assigns number to characterize how closely a cancer resembles normal tissue
grade is guide to aggressiveness of tumor cells
determines prognosis
guide formulation of the treatment plan

70
Q

Grading

A

1- low grade or well-differentiated (slow growing)
2 - intermediate/moderate grade or moderately differentiated (faster than normal cells)
3- High grade or poorly differentiated (fast growing)
4- Undifferentiated (do not resemble normal cells at all)

71
Q

Types of staging

A

Clinical staging

Pathologic staging

72
Q

Clinical staging

A

based on radiologic imaging and physical exam

73
Q

pathologic staging

A

based on biopsy

not as common with newer scanning techniques

74
Q

TNM staging

A

determines extent of cancer
determines prognosis and treatment options
comparison stats
statify for clinical trials

75
Q

TNM

A

Used for most solid tumors
T- tumor, indicates size, depth of invasion and local extension
N- nodes, distinguishes whether there is tumor in regional lymph nodes
M- metastasis, present or absent

Tumor
Nodes
Mets

76
Q

AJCC stating guide

A

based on TNM ratings
tumor placed into one stage
Stage O - insitu, indicates tumor contained at site of devo.
Stage I-IV - varies, based on invasiveness

77
Q

Local
Regional
Distant

A

local - in spot
regional - few lymph involved
distant - mets to lung, brain, bone

78
Q

SEER Staging

A
NCI
groups into 5 main categories using summary staging
-In situ
-Localized
-Regional
-Distant
-Unknown
79
Q
Seer:
In situ
Localized
Regional
Distant
Unknown
A

In situ - abn cells only in payer where developed
Localized - limited to organ of origin
Regional - spread from primary site to nearby lymph or organ tissue
Distant - spread to distant organs or nodes
unknown - not enough info to determine (33%)

80
Q

Ann Arbor staging

A
*for Hodgkin's lymphoma
I - single LN region
II - One side of diaphragm
III - both sides of diaphragm
IV - disseminated

A no systemic (constitutional) symptoms
B fever, night sweats, weight loss

E extra lymphatic sites (tissue outside of lymph)
S splenic disease

81
Q

Testicular Cancer Risk staging

A

Good to poor

82
Q

Recurrence and Autopsy

A

staging indicated
-with cancer recurrence
-assess the extent of the disease
Autopsy allows for a final and most complete staging